Return on Investments: An indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity. Calculated as: Income from Continuing Operations / (Total Long-Term Debt + Shareholders Equity)
Apellis Pharmaceuticals, Inc. (APLS) had Return on Investments of -8.06% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$199.91M |
|
$-58.95M |
|
$29.72M |
|
$170.19M |
|
$251.06M |
|
$-51.14M |
|
$-7.50M |
|
$-58.64M |
|
$-58.64M |
|
$-58.95M |
|
$-58.95M |
|
$-58.95M |
|
$-58.95M |
|
$-51.14M |
|
$-50.16M |
|
126.14M |
|
129.85M |
|
$-0.46 |
|
$-0.40 |
|
| Balance Sheet Financials | |
$1.01B |
|
$1.71M |
|
$60.42M |
|
$1.08B |
|
$323.60M |
|
$361.66M |
|
$381.51M |
|
$705.11M |
|
$370.15M |
|
$370.15M |
|
$370.15M |
|
126.62M |
|
| Cash Flow Statement Financials | |
$45.33M |
|
$-0.31M |
|
$8.88M |
|
$412.61M |
|
$467.76M |
|
$55.15M |
|
$104.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.14 |
|
-- |
|
-- |
|
0.49 |
|
1.23 |
|
85.13% |
|
-25.58% |
|
-25.58% |
|
-- |
|
-29.33% |
|
-29.49% |
|
$45.01M |
|
-- |
|
-- |
|
-- |
|
0.19 |
|
0.21 |
|
0.55 |
|
164.87 |
|
-15.93% |
|
-15.93% |
|
-5.48% |
|
|
Return on Investments |
-8.06% |
$2.92 |
|
$0.35 |
|
$0.35 |
|